Working… Menu

Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00267943
Recruitment Status : Completed
First Posted : December 22, 2005
Last Update Posted : November 13, 2013
Information provided by:
Boehringer Ingelheim

Brief Summary:
The primary objective is to assess the efficacy and safety of the fixed dose combination of telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25) alone or in addition to other antihypertensive therapies during open-label, long-term treatment.

Condition or disease Intervention/treatment Phase
Hypertension Drug: telmisartan 80 mg + hydrochlorothiazide 25 mg Phase 3

Detailed Description:

Patients with a history of hypertension who completed a preceding trial (number 502.480) within the previous fourteen (14) days will be considered for entry to this long-term open-label trial. All patients will receive 'T80/H25'. Additional antihypertensive therapy will be allowed if the patients' blood pressure is not well controlled. [In the preceding double-blind trial 502.480, patients who failed to respond to the fixed dose combination of telmisartan 80 mg '+' hydrochlorothiazide 12.5 mg (T80/H12.5) were randomised to 'T80/H12.5' or T80H25 for eight weeks.] This is a multi-centre, multinational trial with approximately 80 study centres participating. Only study centres participating in the preceding trial 502.480 can enter patients into this open-label trial. It is anticipated that a maximum of 480 patients will be entered into the trial in seventeen countries. Each trial centre is expected to enter between four and twenty-four patients.

Enrollment of patients into this trial will finish when the last patient completes the preceding trial 502.480. At this time, centres will be notified of the termination of recruitment and will not be authorized to include any further patients.

Patients will visit the clinic one month, three months and six months later for assessment of their blood pressure and general health. Their participation in the study is complete six months after the start of the treatment period.

Study Hypothesis:

No statistical hypothesis will be tested. Descriptive statistics will be used to characterise the effects of treatment with T80/H25 with and without other antihypertensive treatments.


The proportion of patients achieving DBP control will be summarised by the total number of patients in the trial as well as by the maximum achieved dose level according to the two categories of T80/H25 alone (T80/H25) and with other antihypertensive medication added (T80/H25/other). An additional sub-group summary by the treatment group in the preceding trial 502.480 (T80/H12.5 and T80/H25) will also be presented.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 639 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 80 mg + Hydrochlorothiazide 25 mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.
Study Start Date : January 2006
Actual Primary Completion Date : January 2007
Study Completion Date : January 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Proportion of patients achieving diastolic blood pressure (DBP) control 24 hours after last dose [ Time Frame: at 6 months ]

Secondary Outcome Measures :
  1. Change from baseline in trough seated DBP. [ Time Frame: at 6 months ]
  2. Change from baseline in trough seated systolic blood pressure (SBP) [ Time Frame: at 6 months ]
  3. Proportion of patients achieving DBP response (trough seated DBP<90 mmHg or trough seated DBP reduction from baseline ≥10 mmHg) [ Time Frame: at 6 months ]
  4. Proportion of patients achieving SBP response (trough seated SBP<140 mmHg or trough seated SBP reduction from baseline ≥10 mmHg) [ Time Frame: at 6 months ]
  5. Proportion of patients achieving SBP response (trough seated SBP<140 mmHg or trough seated SBP reduction from baseline ≥20 mmHg) [ Time Frame: at 6 months ]
  6. Proportion of patients in the trough seated BP category optimal [ Time Frame: at 6 months ]
  7. Proportion of patients in the trough seated BP category normal [ Time Frame: at 6 months ]
  8. Proportion of patients in the trough seated BP category high-normal [ Time Frame: at 6 months ]
  9. Proportion of patients in the trough seated BP category high [ Time Frame: at 6 months ]
  10. Proportion of patients requiring additional antihypertensive therapy to achieve DBP control [ Time Frame: at 6 months ]
  11. Additional reduction in BP by the use of additional antihypertensive therapy [ Time Frame: at 6 months ]
  12. Time to starting additional antihypertensive therapy [ Time Frame: within 6 months ]
  13. Incidence and intensity of Adverse events [ Time Frame: 6 month ]
  14. Physical examinations [ Time Frame: 6 month ]
  15. Change in laboratory parameters [ Time Frame: 6 month ]
  16. 12-Lead Electrocardiogramm ECG [ Time Frame: 6 month ]
  17. Vital Signs (pulse rate, SBP, DBP) [ Time Frame: 6 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Essential hypertension.
  • Currently taking between one and three antihypertensive medications at a stable dose for at least four weeks before Visit 1 of preceding trial 502.480.
  • Blood pressure not adequately controlled on existing treatment before entry to preceding trial 502.480 (inadequate control defined as seated DBP >= 95 mmHg on one current antihypertensive medication or DBP >= 90 mmHg on two or more current antihypertensive medications).
  • Failure to respond to six weeks run-in treatment with T80/H12.5 in preceding trial 502.480. (Failure to respond defined as seated DBP >= 90 mmHg.)
  • Willing and able to provide written informed consent.

Exclusion criteria:

  • Women of child-bearing potential NOT practising acceptable means of birth control, positive serum pregnancy test, breastfeeding.
  • Known or suspected secondary hypertension.
  • Clinically significant change in ECG reported as adverse event in preceding trial 502.480.
  • Any medical condition developing in preceding trial 502.480 that could be worsened by telmisartan/HCTZ (80/25).
  • Discontinuation from preceding 502.480 trial for adverse event or any other reason.
  • Mean SBP >= 200 mmHg.
  • Severe hepatic or renal impairment.
  • Bilateral renal artery stenosis (or in a solitary kidney), post-renal transplant or only one functioning kidney.
  • Clinically relevant hypokalaemia or hyperkalaemia.
  • Uncorrected volume or sodium depletion, primary aldosteronism.
  • Hereditary fructose intolerance.
  • Previous symptoms of angioedema after ACE inhibitors or angiotensin-II receptor antagonists.
  • Drug or alcohol dependency within the six months prior to entry to 502.480. concurrent participation in another clinical trial or any investigational therapy.
  • Hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.
  • Allergic hypersensitivity to any component of the formulations under investigation.
  • Concomitant therapy with lithium, cholestyramine or colestipol resins.
  • Non-compliance with study medication (less than 80% or more than 120%) during the preceding 502.480 trial.
  • Any other clinical condition which, in the opinion of the investigator, would not allow safe administration of telmisartan or hydrochlorothiazide.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00267943

Show Show 78 study locations
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Study Coordinator BIL UK / Ireland
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00267943    
Other Study ID Numbers: 502.491
First Posted: December 22, 2005    Key Record Dates
Last Update Posted: November 13, 2013
Last Verified: November 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists